Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Connect with investors, share insights, and grow together
Stay up to date on latest investing trends and other announcements
Explore our range of financial tools to streamline your investment planning
A structured, comprehensive way to understand global investing
Read about our journey and get to know the leadership team at Vested
The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials. more
| Time Frame | SBIO | S&P500 |
|---|---|---|
| 1-Week Return | 3.67% | 0.01% |
| 1-Month Return | 33.05% | 3.54% |
| 3-Month Return | 24.53% | 10.58% |
| 6-Month Return | 31.93% | 8.03% |
| 1-Year Return | 105.47% | 20.06% |
| 3-Year Return | 113.86% | 70.98% |
| 5-Year Return | 38.51% | 71.89% |
| 10-Year Return | 184.23% | 252.66% |
| Time Frame | SBIO | S&P500 |
|---|---|---|
| 1-Week Return | 554.93% | 0.52% |
| 1-Month Return | 3,127.36% | 52.69% |
| 3-Month Return | 143.44% | 50.36% |
| 6-Month Return | 75.40% | 16.96% |
| 1-Year Return | 105.47% | 20.06% |
| 3-Year Return | 28.84% | 19.58% |
| 5-Year Return | 6.73% | 11.44% |
| 10-Year Return | 11.01% | 13.43% |
| Stock name | Ticker | Weight |
|---|---|---|
Crinetics Pharmaceuticals Inc.
|
CRNX |
4.49%
|
Apogee Therapeutics Inc.
|
APGE |
4.22%
|
Xenon Pharmaceuticals Inc.
|
XENE |
3.39%
|
CG oncology Inc.
|
CGON |
3.39%
|
Dianthus Therapeutics Inc.
|
DNTH |
2.72%
|
Travere Therapeutics Inc.
|
TVTX |
2.68%
|
Oruka Therapeutics Inc.
|
ORKA |
2.67%
|
Definium Therapeutics Inc.
|
DFTX |
2.62%
|
VeraDermics Inc.
|
MANE |
2.54%
|
Edgewise Therapeutics Inc.
|
EWTX |
2.5%
|
ACADIA Pharmaceuticals Inc.
|
ACAD |
2.29%
|
Relay Therapeutics Inc.
|
RLAY |
2.23%
|
Newamsterdam Pharma Co. NV
|
NAMS |
2.1%
|
Denali Therapeutics Inc.
|
DNLI |
2.08%
|
Dyne Therapeutics Inc.
|
DYN |
1.98%
|
Structure Therapeutics Inc.
|
GPCR |
1.94%
|
Ideaya Biosciences Inc.
|
IDYA |
1.66%
|
Celldex Therapeutics Inc.
|
CLDX |
1.56%
|
Vera Therapeutics Inc.
|
VERA |
1.54%
|
Disc Medicine Inc.
|
IRON |
1.49%
|
MBX Biosciences Inc.
|
MBX |
1.48%
|
Kailera Therapeutics Inc.
|
KLRA |
1.37%
|
BioCryst Pharmaceuticals Inc.
|
BCRX |
1.36%
|
Immunome Inc.
|
IMNM |
1.35%
|
Mineralys Therapeutics Inc.
|
MLYS |
1.28%
|
Tarsus Pharmaceuticals Inc.
|
TARS |
1.27%
|
Agios Pharmaceuticals Inc.
|
AGIO |
1.25%
|
Vericel Corp.
|
VCEL |
1.22%
|
Nektar Therapeutics
|
NKTR |
1.21%
|
SELLAS Life Sciences Group Inc.
|
SLS |
1.21%
|
Zai Lab Ltd.
|
ZLAB |
1.14%
|
Viridian Therapeutics Inc.
|
VRDN |
1.11%
|
Palvella Therapeutics Inc.
|
PVLA |
1.05%
|
Sionna Therapeutics Inc.
|
SION |
1.04%
|
Nuvation Bio Inc.
|
NUVB |
1.03%
|
Sarepta Therapeutics Inc.
|
SRPT |
1.02%
|
Rapport Therapeutics Inc.
|
RAPP |
1.02%
|
Amylyx Pharmaceuticals Inc.
|
AMLX |
1.01%
|
Lakefront Biotherapeutics NV
|
LKFT |
1%
|
Stoke Therapeutics Inc.
|
STOK |
1%
|
Tyra Biosciences Inc.
|
TYRA |
1%
|
Bicara Therapeutics Inc.
|
BCAX |
0.97%
|
Compass Pathways PLC
|
CMPS |
0.94%
|
Generate Biomedicines Inc.
|
GENB |
0.94%
|
Taysha Gene Therapies Inc.
|
TSHA |
0.93%
|
Zenas Biopharma Inc.
|
ZBIO |
0.92%
|
Maze Therapeutics Inc.
|
MAZE |
0.86%
|
Immunocore Holdings PLC
|
IMCR |
0.83%
|
ArriVent Biopharma Inc.
|
AVBP |
0.8%
|
Corvus Pharmaceuticals Inc.
|
CRVS |
0.68%
|
Immatics NV
|
IMTX |
0.66%
|
MannKind Corp.
|
MNKD |
0.65%
|
MeiraGTx Holdings PLC
|
MGTX |
0.63%
|
WaVe Life Sciences Ltd.
|
WVE |
0.61%
|
Xencor Inc.
|
XNCR |
0.6%
|
Seaport Therapeutics Inc.
|
SPTX |
0.59%
|
Olema Pharmaceuticals Inc.
|
OLMA |
0.53%
|
Vor BioPharma Inc.
|
VOR |
0.53%
|
Solid Biosciences Inc.
|
SLDB |
0.53%
|
Kura Oncology Inc.
|
KURA |
0.52%
|
Geron Corp.
|
GERN |
0.49%
|
Design Therapeutics Inc.
|
DSGN |
0.49%
|
LB Pharmaceuticals Inc.
|
LBRX |
0.48%
|
Alto Neuroscience Inc.
|
ANRO |
0.48%
|
Theravance Biopharma Inc.
|
TBPH |
0.45%
|
Climb Bio Inc.
|
CLYM |
0.41%
|
Rigel Pharmaceuticals Inc.
|
RIGL |
0.4%
|
Aclaris Therapeutics Inc.
|
ACRS |
0.4%
|
Oculis Holding AG
|
OCS |
0.4%
|
SpyGlass Pharma Inc.
|
SGP |
0.39%
|
Candel Therapeutics Inc.
|
CADL |
0.36%
|
Allogene Therapeutics Inc.
|
ALLO |
0.35%
|
Relmada Therapeutics Inc.
|
RLMD |
0.34%
|
Tectonic Therapeutic Inc.
|
TECX |
0.33%
|
AgomAb Therapeutics NV
|
AGMB |
0.33%
|
4D Molecular Therapeutics Inc.
|
FDMT |
0.33%
|
Neurogene Inc.
|
NGNE |
0.32%
|
Altimmune Inc.
|
ALT |
0.3%
|
Fulgent Genetics Inc.
|
FLGT |
0.3%
|
Eikon Therapeutics Inc.
|
EIKN |
0.29%
|
Contineum Therapeutics Inc.
|
CTNM |
0.25%
|
Zura Bio Ltd.
|
ZURA |
0.25%
|
Evommune Inc.
|
EVMN |
0.24%
|
Tenax Therapeutics Inc.
|
TENX |
0.24%
|
Rezolute Inc.
|
RZLT |
0.23%
|
Delcath Systems Inc.
|
DCTH |
0.23%
|
C4 Therapeutics Inc.
|
CCCC |
0.23%
|
Compass Therapeutics Inc.
|
CMPX |
0.22%
|
X4 Pharmaceuticals Inc.
|
XFOR |
0.21%
|
Upstream Bio Inc.
|
UPB |
0.21%
|
Enanta Pharmaceuticals Inc.
|
ENTA |
0.2%
|
Akebia Therapeutics Inc.
|
AKBA |
0.19%
|
Immuneering Corp.
|
IMRX |
0.17%
|
SAB Biotherapeutics Inc.
|
SABS |
0.15%
|
MacroGenics Inc.
|
MGNX |
0.14%
|
Inhibikase Therapeutics Inc.
|
IKT |
0.14%
|
Protara Therapeutics Inc.
|
TARA |
0.12%
|
Fulcrum Therapeutics Inc.
|
FULC |
0.12%
|
Anavex Life Sciences Corp.
|
AVXL |
0.12%
|
Bicycle Therapeutics PLC
|
BCYC |
0.11%
|
NovaBridge Biosciences
|
NBP |
0.11%
|
Immunic Inc.
|
IMUX |
0.1%
|
Arcturus Therapeutics Holdings Inc.
|
ARCT |
0.1%
|
Novo Nordisk A/S
|
Novo.Nordisk.A.S |
0%
|
AstraZeneca PLC
|
AstraZeneca.PLC |
0%
|
Chinook Therapeutics Inc.
|
Chinook.Therapeutics.Inc. |
0%
|
Cash Equivalent
|
USD |
0%
|
| Sector | Weight |
|---|---|
|
Health care
|
99.99% |
|
All Others
|
0.01% |
ALPS Medical Breakthroughs ETF (SBIO) share price today is $67.22.
Yes, Indians can buy shares of ALPS Medical Breakthroughs ETF (SBIO) on Vested. To buy SBIO from India, you can open a US Brokerage account by signing up on Vested. The account opening process is completely digital and secure, and takes 3-5 minutes to complete.
Yes, you can purchase fractional shares of ALPS Medical Breakthroughs ETF (SBIO) on Vested. You can start investing in ALPS Medical Breakthroughs ETF (SBIO) with a minimum investment of $1.
The 52-week high price of ALPS Medical Breakthroughs ETF (SBIO) is $69.07. The 52-week low price of ALPS Medical Breakthroughs ETF (SBIO) is $32.21.
The stock symbol (or ticker) of ALPS Medical Breakthroughs ETF is SBIO.
Yes, you can setup SIP in ALPS Medical Breakthroughs ETF shares. Follow the below steps to create the SIP:
Here is the historical performance of SBIO on the Vested app.
The expense ratio of ALPS Medical Breakthroughs ETF (SBIO) is 0.5%.
Link copied